Frontiers in endocrinology

A decade of progress in type 2 diabetes and heart disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Essence

This notice records a correction to a review on type 2 diabetes, cardiovascular disease, SGLT2 inhibitors, and GLP-1 receptor agonists.

Evidence

This is a correction notice for the article identified by DOI 10.3389/fendo.2025.1605746.

Caveat

The abstract provides no corrected content, review findings, or diabetes and cardiovascular outcome details to summarize.

Simplified

Full Text

What this is

  • This document corrects omissions in the author affiliations of a previously published article.
  • The affiliations for David Alexander Vernaza Trujillo were not included in the original publication.
  • The erratum ensures proper attribution and acknowledgment of the author's institutional affiliations.

Essence

  • The erratum corrects the omission of author affiliations in a prior article regarding type 2 diabetes and cardiovascular disease.

Simplified

Related papers

Jul '25
Ten years of progress in type 2 diabetes and heart disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists
top 10% journal
cited by 4 papers
journal article
May '25
Glucagon-like peptide-1 drugs vs. sodium/glucose transporter inhibitors for reducing kidney failure and death in type 2 diabetes patients with kidney disease
top 5% journal
cited by 6 papers
comparative study
Feb '25
How Age and Sex Affect the Success of Type 2 Diabetes Treatments
top 1% journal
cited by 33 papers
systematic review
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
May '25
Stopping treatment with two diabetes drug types in a national group of people with type 2 diabetes
top 2% journal
cited by 12 papers
journal article
Aug '25
Comparing kidney and heart health outcomes of diabetes treatments in people with chronic kidney disease
cited by 3 papers
systematic review
Jun '25
Comparing three diabetes treatments and their effects on type 2 diabetes with heart failure
top 10% journal
cited by 2 papers
systematic review
Dec '24
SGLT2 inhibitors reduce heart fat more than GLP-1 drugs or exercise in people with type 2 diabetes or obesity
top 5% journal
cited by 25 papers
systematic review
Aug '25
How SGLT2 inhibitors and GLP-1 receptor agonists relate to death rates in diabetic patients with heart disease
top 2% journal
cited by 7 papers
multicenter study

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
yesterday7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
1 week ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
2 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
3 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
4 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
5 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
6 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
7 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
8 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief